|
Abelcet Injection Liposome ; Accutane Accutane Capsules Aceon Tablets 2 mg, 4 mg, 8 mg ; Aciphex Tablets Acromycin V Actifed with Codiene Cough Syrup Actiq Anesta ; Actonel Tablets Adalat CC Aggrenox Capsules Agrylin Capsules Alferon N Injection Interferon ; Alka-Seltzer Original Antacid and Pain Reliever Effervescent Tablets Alka-Seltzer Cherry Antacid and Pain Reliever Effervescent Tablets Alka-Seltzer Lemon Lime Antacid and Pain Reliever Effervescent Tablets Alka-Seltzer Extra Strength Antacid and Pain Reliever Effervescent Tablets Alka-Seltzer Effervescent Tablets Alferon N Alumadrine Tablets Altace Alumadrine Tablets Ambien Amerge Tablets Amicar Anatranil Anaprox and Anaprox DS Anestacon Ansaid Anzemet Injection Anzemet Tablets Aralen Injection Aralen Tablets Arithritis Strength BC Powder Aricept Tablets Aricept Tablets Arthrotec Tablets Asacol Ascriptin A D Ascriptin Asendin Aspirin Atacand HCT Tablets Atretol Atrofen Atrovent Nasal Spray Atrohist Plus Avelox Tablets Azactam Tablets Azactam for Injection Azo Gantanol Azo Gantrisin Azulfidine EN-tabs Tablet BC Powder Bactrim DS Bactrim I.V. Bactrim Arthritis Strength BC Powder Benadryl Parenteral Betaxon Ophthalmic Suspension Biaxin Filmtab Tablets Biaxin for Oral Suspension Biaxin XL Filmtab Tablets Bicillin L-A Injection Buprenex Injectable Blocadren BuSpar Calan Tablets Calan SR Caplets Cama Capastat Sulfate Carbocaine Hydrochloride Carbatrol Capsules Cardene Cardioquin Cardizem Cardura Cartrol Cataflam Celebrex Capsules Celebrex Capsules Celexa Oral Suspension Celexa Tablets CellCept Capsules CellCept Intravenous CellCept Oral Suspension Pagina 1 di 5.
Hymn-book; and if you're faithful to the Lord, he'll be faithful to you." So speaks the poor soul, in sore discouragement; for she knows that to-morrow any man, however vile and brutal, however godless and merciless, if he only has money to pay for her, may become owner of her daughter, body and soul; and then, how is the child to be faithful? She thinks of all this, as she holds her daughter in her arms, and wishes that she were not handsome and attractive. It seems almost an aggravation to her to remember how purely and piously, how much above the ordinary lot, she has been brought up. But she has no resort but to pray; and many such prayers to God have gone up from those same trim, neatly-arranged, respectable slave-prisons, --prayers which God has not forgotten, as a coming day shall show; for it is written, "Who causeth one of these little ones to offend, it were better for him that a mill-stone were hanged about his neck, and that he were drowned in the depths of the sea." The soft, earnest, quiet moonbeam looks in fixedly, marking the bars of the grated windows on the prostrate, sleeping forms. The mother and daughter are singing together a wild and melancholy dirge, common as a funeral hymn among the slaves.
Anzemet veterinary
As stated in section 2.18, data on cough and spasmodic cough were available for all 1 825 children born from 1996 until September 30, 2006, whereof 924 were infants. All children but 3 were coughing during their pertussis episode, including 2 infants. Applying the EU and current WHO clinical case definition of pertussis with 2 weeks of more of coughing any type ; in conjunction with positive laboratory sample, in all 1 782 1 ; would fulfil this definition. Among the 43 cases that would not fulfil the EU or WHO definitions, 21 were infants and 22 children aged 1-6 years. All but two of those infants had received erythromycin or trimetoprim-sulfametoxazol, whereas fourteen of the 22 children aged 1-6 years were treated with antibiotics. Seven of those infants were unvaccinated, 3 had received one dose and 11 had received two doses. One child aged one year had received only two doses and the remaining children aged 1-6 years had received three doses.
Table B lists some of the factors that should be taken into account in making this decision. ARVs in FDCs and blister packs have potential advantages over conventional drug packaging: they are helpful tools for simplifying treatment and promote adherence. Moreover, they can minimize prescription errors, improve adherence of health care workers to treatment standards, decrease errors in drug administration, improve drug management because of fewer items and a single expiration date ; , simplify drug forecasting, procurement, distribution and stocking because fewer items and lower volumes are necessary, and reduce the risk of misuse of single drugs. FDCs also present challenges with respect to the individualization of dosing of individual components, the treatment of children and the differential half-lives of drugs when treatment is interrupted. Laboratory monitoring requirements should also be taken into account see Section VI ; . When d4T 3TC NVP or ZDV 3TC NVP is chosen as the first-line regimen the availability of the two-drug combination d4T 3TC or ZDV 3TC ; is also important for use with NVP lead-in dosing during the first two weeks of treatment and for managing some toxicities associated with NVP Annex D ; . Additional drugs should be available in districts level 2 ; or regional hospitals level 3 ; . This tiered approach to ARV regimen availability can be paralleled by a tiered monitoring strategy for health care systems see Section VI.
12. Kohner EM, Aldington SJ, Stratton IM, Manley SE, Holman RR, Matthews DR, Turner RC. United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. Arch Ophthalmol. 1998 Mar; 116 3 ; : 297303.
Anzemet 100mg
Subject: Stimson library - OVID System search results for "Common cardiac prosthetic valves. Radiological identification and associated complications." Document Type: Search Printout; Abstract. Document Date: 1996 and apidra.
Table 7 shows the age of the Druglijn-callers. The youngest caller was 11 years old, the oldest 78. Table 7. Age of Druglijn-callers. Age in years ; 16 - 25 Total % 5 31 17.
NEAR VA DISTANCE NEAR BIF VARIF N4.5 Distance OMB DIST H NEAR H NPC Ortho Ortho 6cm V V ortho ortho IOP R L TIME MEAN OF READINGS and apomorphine.
| Anzemet litigationOwens R: Risk assessment for antimicrobial agent-induced QTc prolongation and torsades de pointes. Pharmacother 2001k; 21 3 ; : 310-319. Owens R: Risk assessment for antimicrobial agent-induced QTc prolongation and torsades de pointes. Pharmacother 2001l; 21 3 ; : 310-319. Owens R: Risk assessment for antimicrobial agent-induced QTc prolongation and torsades de pointes. Pharmacother 2001m; 21 3 ; : 310-319. Owens R: Risk assessment for antimicrobial agent-induced QTc prolongation and torsades de pointes. Pharmacother 2001n; 21 3 ; : 310-319. Owens R: Risk assessment for antimicrobial agent-induced QTc prolongation and torsades de pointes. Pharmacother 2001o; 21 3 ; : 310-319. Owens R: Risk assessment for antimicrobial agent-induced QTc prolongation and torsades de pointes. Pharmacother 2001p; 21 3 ; : 310-319. Owens R: Risk assessment for antimicrobial agent-induced QTc prolongation and torsades de pointes. Pharmacother 2001q; 21 3 ; : 310-319. Owens R: Risk assessment for antimicrobial agent-induced QTc prolongation and torsades de pointes. Pharmacother 2001r; 21 3 ; : 310-319. Owens R: Risk assessment for antimicrobial agent-induced QTc prolongation and torsades de pointes. Pharmacother 2001s; 21 3 ; : 310-319. Owens R: Risk assessment for antimicrobial agent-induced QTc prolongation and torsades de pointes. Pharmacother 2001t; 21 3 ; : 310-319. Owens R: Risk assessment for antimicrobial agent-induced QTc prolongation and torsades de pointes. Pharmacother 2001u; 21 3 ; : 310-319. Owens R: Risk assessment for antimicrobial agent-induced QTc prolongation and torsades de pointes. Pharmacother 2001v; 21 3 ; : 310-319. Owens R: Risk assessment for antimicrobial agent-induced QTc prolongation and torsades de pointes. Pharmacother 2001w; 21 3 ; : 310-319. Owens R: Risk assessment for antimicrobial agent-induced QTc prolongation and torsades de pointes. Pharmacother 2001x; 21 3 ; : 310-319. Owens R: Risk assessment for antimicrobial agent-induced QTc prolongation and torsades de pointes. Pharmacother 2001y; 21 3 ; : 310-319. Owens R: Risk assessment for antimicrobial agent-induced QTc prolongation and torsades de pointes. Pharmacother 2001z; 21 3 ; : 310-319. Pacher P & Kecskemeti V: Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?. Curr Pharm Des 2004; 10 20 ; : 2463-2475. Pae CU, Lee SJ, Lee CU, et al: A pilot trial of quetiapine for the treatment of patients with delirium. Hum Psychopharmacol 2004; 19 2 ; : 125-127. Patel NC, Kistler JS, James EB, et al: A retrospective analysis of the short-term effects of olanzapine and quetiapine on weight and body mass index in children and adolescents. Pharmacotherapy 2004; 24 7 ; : 823-830. Product Information: Anzemet R ; , dolasetron. Hoechst Marion Roussel, Kansas City, MO, 1997. Product Information: Anzemet R ; , dolasetron. Hoechst Marion Roussel, Kansas City, MO, 1997a. Product Information: Aralen R ; , chloroquine phosphate. Sanofi Pharmaceuticals, New York, NY, 2001. Product Information: Biaxin R ; , clarithromycin. Abbott Laboratories, North Chicago, IL, 2002. Product Information: Cerebyx R ; , fosphenytoin sodium injection. Parke-Davis, Division of Warner-Lambert, Morris Plains, NJ, 1999. Product Information: Compazine R ; , prochlorperazine maleate spansule. GlaxoSmithKline, Research Triangle Park, NC, 2002. Product Information: DynaCirc R ; , isradipine. Novartis Pharmaceuticals Corporation, East Hanover, NJ, 2000. Product Information: Effexor R ; XR, venlafaxine. Wyeth-Ayerst Laboratories, Philadelphia, PA, 2000. Product Information: Factive R ; , gemifloxacin. Genesoft Pharmaceuticals, Seoul, Korea, 2003. Product Information: Foscavir R ; , foscarnet. AstraZeneca, Inc., Alexandria, VA, 1998. Product Information: Geodon TM ; , ziprasidone. Pfizer Inc., NY, NY, 2002. Product Information: Geodon TM ; , ziprasidone. Pfizer Inc., NY, NY, 2002a. Product Information: Geodon TM ; , ziprasidone. Pfizer Inc., NY, NY, 2002b. Product Information: Haldol R ; , haloperidol decanoate for injection. Ortho-McNeil Pharmaceutical Corp., Raritan, NJ, 2001a. Product Information: Haldol R ; , haloperidol decanoate. McNeil Pharmaceutical, Inc., Raritan, NJ, 1998. Product Information: Haldol R ; , haloperidol decanoate. McNeil Pharmaceutical, Inc., Raritan, NJ, 1998a. Product Information: Haldol R ; , haloperidol decanoate. McNeil Pharmaceutical, Inc., Raritan, NJ, 1998b. Product Information: Haldol R ; , haloperidol decanoate. McNeil Pharmaceutical, Inc., Raritan, NJ, 1998c. Product Information: Haldol R ; , haloperidol decanoate. McNeil Pharmaceutical, Inc., Raritan, NJ, 1998d. Product Information: Haldol R ; , haloperidol decanoate. McNeil Pharmaceutical, Inc., Raritan, NJ, 1998e. Product Information: Haldol R ; , haloperidol decanoate. McNeil Pharmaceutical, Inc., Raritan, NJ, 1998f. Product Information: Haldol R ; , haloperidol decanoate. McNeil Pharmaceutical, Inc., Raritan, NJ, 1998g. Product Information: Haldol R ; , haloperidol decanoate. McNeil Pharmaceutical, Inc., Raritan, NJ, 1998h. Product Information: Haldol R ; , haloperidol decanoate. Ortho McNeil Pharmaceutical, Inc., Raritan, NJ, 2001. Product Information: Halfan R ; , halofantrine hydrochloride. Research Triangle Park, NC, 1998. Product Information: Hismanal R ; , astemizole. Janssen Pharmaceutica, Inc., Titusville, NJ, 1996. Product Information: Inapsine R ; , droperidol. Akorn, Inc., Decatur, IL, 2002. Product Information: Lariam R ; , mefloquine. Roche Laboratories, Nutley, NJ, 1999. Product Information: Lorelco R ; , probucol. Marion Merrell Dow, Kansas City, MO, 1991. Product Information: Mellaril R ; , thioridazine. Mylan Pharmaceuticals Inc., Morgantown, WV, 2001. Product Information: Nipolept R ; , zotepine. Klinge Pharma GmbH, Munich, 1996. Product Information: Nipolept R ; , zotepine. Klinge Pharma GmbH, Munich, 1996a. Product Information: Norpace R ; , disopyramide. G.D. Searle & Co., Chicago, IL, 1997. Product Information: Orap R ; , pimozide. Gate Pharmaceuticals, Sellersville, PA, 1999. Product Information: Orap R ; , pimozide. Gate Pharmaceuticals, Sellersville, PA, 1999a. Product Information: Orap R ; , pimozide. Gate Pharmaceuticals, Sellersville, PA, 1999b.
References 1. Goldstein D., Shianna K., et al. Searching the genome for determinants of response to HIV. Workshop 3a. 2. Shianna K. Genotyping technologies: small and large scale studies. Workshop 3b. 3. Telenti A. Practical applications in HIV disease. Workshop 3c. 4. Malik H., Emerman M. Intrinsic immunity against retroviruses in primate genomes: evolutionary retrospectives and prospectives. Workshop 3d and aprepitant.
Provisions We recognize provisions for current and deferred taxes, personnel costs as well as environmental warranty and litigation risks when we have a present obligation as a result of a past event and it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Long-term provisions are reported at their discounted value. The determination of probabilities is based on past experience and the circumstances known at the time of decision, but also requires subjective management judgement. As a consequence, the actual liability might be significantly higher. Accounting for expected third-party claims Provisions for third-party claims include mainly indemnities relating to the sale of business activities. During fiscal year 2002, we completed the sale of our 24% ownership interest in Aventis CropScience to Bayer AG. The purchase agreement contained a range of indemnities and representations and warranties, relating mainly to financial statement guarantees, environmental matters, tax liabilities, the funding of employee benefit plans, social contributions and product liabilities. This accounting issue was considered as a gain recognition issue. Recognition of a gain on the sale of a business is prohibited, if the significant risks of ownership are not transferred to the buyer and the costs incurred in respect of the transaction can not be measured reliably. Consequently we realized a gain on the transaction net of the claims we expect to be filed by the buyer through the recognition of a contingent liability. The possible indemnities, repesentations and warranties are uncertain in nature. Therefore, the estimation of the amount of expected claims requires subjective assumptions and management judgement. The actual outcome regarding the filing of claims as well as the actual amount attributable to a filed claim might differ significantly from management's expectations. Impairment of long-lived assets We review our long-lived assets for impairment, including identifiable intangibles and goodwill, whenever events or changes in circumstances indicate triggering event ; that the carrying amount of the asset may not be recoverable. In order to assess if assets are impaired, we estimate the recoverable amount of the asset by the higher of either the present value of future cash flows expected to result from the use of the asset value in use ; or its net selling price. If the recoverable amount is less than the carrying amount of the asset, we will recognize an impairment loss for the amount by which the asset's carrying amount exceeds its recoverable amount. For purposes of determining the value in use, we group our assets at the lowest level for which separately identifiable cash flows are available. For estimating future cash flows, we use our internal budgets. Thereby, considerable management judgement is necessary to identify a triggering event and to estimate future sales and cost of sales which underly the present value of future cash flows. Accordingly, actual outcomes could vary significantly from such estimates. Factors such as changes in the planned use of assets or closing of facilities or lower than anticipated sales for products could result in shortened useful lives or impairments. Pension plans We account for pensions in accordance with actuarial valuations, which rely on statistical and other factors in order to anticipate future events see Note 4 to our Consolidated Financial Statements ; . These factors include key actuarial assumptions about the discount rate and rate of future compensation increases. In addition, our actuarial consultants also make use of subjective assumptions such as fluctuations and mortality rates. These actuarial assumptions may differ materially from actual developments due to changing market and economic conditions, changes in fluctuation rates or changes in live expectancy of participants, thereby resulting in a significant increase of the projected benefit obligation PBO.
|
Amobarbital: Barbiturate Tx: seizure disorders Amodopar methyldopa ; amoxapine: Tricyclic antidepressant Toxicology drug to drug interactions: TCA overdose can cause seizures, however these are generally short-lived In contrast with other TCAs, Amoxapine and Maprotiline can cause status epilepticus amoxicillin: Antibiotic - penicillin Amoxil amoxicillin ; amphotericin B: Antibiotic Tx: life-threatening infections ampicillin: Antibiotic Tx: general infections Ampicin ampicillin ; Ampicin PRB ampicillin + probenecid ; amprenavir: Protease inhibitor. Tx: HIV related infections amrinone: Cardiac Inotropic agent Tx: CHF that does not respond to other treatments Actions: the force of cardiac contractility Also has vasodilatory effects and reduces preload and afterload by directly relaxing vascular smooth muscle in both the venous and arterial systems Amytol sodium amobarbital ; Anacin aspirin + caffeine ; Anacin with Codeine aspirin + caffeine + codeine ; Anacobin cyanocobalamin ; Anadrol-50 oxymetholone ; Anafranil clomipramine ; anagrelide: Platelet inhibitor Tx: Essential thrombocythemia Anaprox naproxen ; Anaprox DS naproxen ; anastrozole: Aromatase inhibitor; blocks conversion of aromatizable steroids to estrogen. Tx: advanced breast cancer Ancasal aspirin ; Ancobon flucytosine ; Ancotil flucytosine ; Androderm testosterone ; Androgel testosterone ; Android-10 or -25 methyltestosterone ; Anexsia hydrocodone + acetominophen ; Anacin acetaminophen ; Ansaid flurbiprofen ; Antabuse disulfiram ; AntibiOtic cortisporin otic ; Antismasmotic atropine + hyoscyamide + phenobarbital + scopolamine ; Antivert merclizine ; Anturane sulfinpyrazone ; Anzemet dolasetron ; Apacet acetaminophen ; Aphthasol amlexanox and apri.
Blast counts WBC 30x109 L ; at diagnosis, cytogenetic chromosomal abnormalities as t 4; 11 ; and t 1; 19 ; , or 7, age 2 or 15 years, central nerve system CNS ; involvement, mediastinal mass, 6 weeks to obtain remission, or relapse during therapy Barrett et al., 1989, Wetzler et al., 1999 ; . Results have improved with time and five-year disease free survival DFS ; are today 59% for patients suffering from AML and transplanted in complete remission CR ; 1. This is results from the International Bone Marrow Transplant Registry IBMTR ; and the corresponding results from the European Group for Blood and Marrow Transplantation EBMT ; are 57%. For children the results are better, 80% 90%, if transplanted early. Other indications for ASCT are chronic myeloid leukemia CML ; in chronic phase CP ; Goldman, 1993 ; if the CML does not respond to Imatinib Glivec ; Pitini et al., 2003 ; . Myeloma grade III has been identified as an indication for ASCT. Intensive myeloablative chemotherapy treatment followed by an autologus transplantation, or an autologus transplantation followed by an allogeneic, is presently evaluated in multicentre studies. Myelodysplastic syndrome MDS ; is a reason for ASCT if the patient does not respond to ordinary treatment, if there are high numbers of blasts in the marrow, or if the patient requires transfusions due to cytopenia. High-risk lymphomas are often treated with autologus transplantations, but in some cases it may be an indication for allogeneic transplantation. Non-malignant indications for ASCT For severe aplastic anemia SAA ; in patients below 40 years of age, early transplantation is preferable if an HLA-identical sibling donor is available. If patients do not respond to first line therapy, antithymocyte globulin ATG ; and cyclosporin or other immunosuppression, they may be treated with an HLA-matched unrelated donor Svenberg et al., 2004 ; . Too many blood transfusions sensitise the patient and increase the risk of graft failure Storb et al., 1977 ; . Patients with immunodeficiencies such as severe SCID do not have a healthy immune defence and are unable to reject the graft. Therefore, conditioning may not be needed in severe cases where transplantation is done upfront using maternal T-cell depleted stem-cells. However, conditioning is recommended for immunodeficiencies using non-maternal grafts. Patients with metabolic diseases diseases with different enzymes produced by hematopoietic cells ; can be helped with stem-cells from a healthy donor Hobbs, 1981, Krivit et al., 1995, Peters et al., 1996, Good, 1975, Good, 1987, Good and Verjee, 2001, Ringden et al., 1988, Hoogerbrugge et al., 1995 ; . These diseases include mucopolysaccharoidoses like Hurler's disease and Maroteaux-Lamy. Patients with Hurler's disease require transplantation before two years of age before too many symptoms, especially from the central nerve system are visible, to give meaningful results Krivit et al., 1995.
Table 1. Selected Toxic Effects According to Treatment Group. * Toxic Effects All Groups N 980 ; Group 1 N 155 ; Group 2 N 155 ; Group 3 N 155 ; Group 4 N 155 ; Group 5 N 178 ; Group 6 N 182 and aptivus.
Holders of ADRs on the relevant record date will be entitled to receive any dividends payable in respect of the ordinary shares underlying the ADRs, subject to the terms of the deposit agreement under which the ADRs are issued. Subject to exceptions provided in the deposit agreement, cash dividends paid in euro will be converted by the depositary to US dollars and paid by the depositary to holders of ADRs, net of conversion expenses of the depositary, and in accordance with the deposit agreement. The rights of holders of ADRs with respect to any dividends or other distributions on the ordinary shares underlying the ADRs will be governed by the deposit agreement and may be different from the rights of holders of ordinary shares. For a discussion of the material German and U.S. Federal income tax provisions regarding the taxation of dividends on the ordinary shares and the ADRs, see "Item 10-Additional Information-Taxation.
Anzemet info
Assessment"[mesh] or dietary guideline or school-based intervention or program or intervention or promotion or policy or nutrition education or prevention or "education"[mesh] or "behavior"[mesh] or "marketing"[mesh] or mass-media or "schools"[mesh] or "communication"[mesh] or "intervention studies"[mesh] or "public policy"[mesh] or "randomized controlled trials"[mesh] or "health education"[mesh] or "government programs"[mesh] or "national health programs"[mesh] or "health promotion"[mesh] or "nutrition policy"[mesh] or "prevention and control"[subheading] or "guidelines"[mesh] or impact or efficacy or effectiv * inclusion exclusion criteria: only high-quality studies were included, that is, those that had an experimental or quasi-experimental design for which the intervention was clearly described and that included tests of statistical significance in the impact analysis and aranesp.
Chapter 4 8- tert-Butyl-diphenyl-silanyloxy ; - 3R, 7S ; -3, 7-dimethyl-octan-1-ol 4.7 ; : 35 To solution of 4.6 870 mg, 1.97 mmol ; in THF 8.5 mL ; at -78 oC was added a solution of Dibal-H 20 wt% in toluene, 8.3 mL, 10.1 mmol, 5.0 eq ; and the TBDPSO o OH resulting mixture was stirred for 2 h at -78 C under argon, after which TLC showed complete conversion. The reaction was quenched with aq. NH4Cl sat. ; and then diluted with Et2O and aq. HCl 1.0 M ; until a clear solution was obtained. The aqueous layer was extracted with Et2O 3x ; and the combined organic layers were washed with aq. NaHCO3 sat. ; and brine sat. ; , dried Na2SO4 ; and concentrated. The product 4.7, 792 mg, 1.92 mmol, 97% ; was isolated as a colorless oil after column chromatography n-pentane-EtOAc 4: 1 ; . 3R, 7S ; -4.7: [ ]D22 + 0.5o c 2.00, CHCl3 ; , 1H-NMR CDCl3, 400 MHz ; 0.88 d, J 6.8 Hz, 3H ; , 0.92 d, J 6.4 Hz, 3H ; , 1.05 s, 9H ; , 1.06-1.70 m, 10H ; , 3.43 dd, J 6.4, 9.6 Hz, 1H ; , 3.51 dd, J 5.6, 9.6 Hz, 1H ; , 3.67 m, 2H ; , 7.35-7.44 m, 6H ; , 7.65-7.68 m, 4H ; ppm. 13CNMR CDCl3, 100.6 MHz ; 16.8 q ; , 19.2 s ; , 19.5 q ; , 24.1 t ; , 26.7 q ; , 29.3 d ; , 33.2 t ; , 35.5 d ; , 37.3 t ; , 39.7 t ; , 61.0 t ; , 68.7 t ; , 127.4 d ; , 129.3 d ; , 133.9 s ; , 135.5 d ; ppm. MS CI ; for C26H40O2Si: m z 430 M + NH4 ; + , HRMS calcd for C26H40O2Si-C4H9: 355.209, found: 355.207. 8-Bromo- 2S, ; -2, 6-dimethyl-octyloxy ; -tert-butyl-diphenyl-silane 4.8 ; : 35 To solution of 4.7 188 mg, 0.46 mmol ; in dichloromethane TBDPSO 1.6 mL ; were added PPh3 143 mg, 0.55 mmol, 1.2 eq ; Br and then NBS 97 mg, 0.55 mmol, 1.2 eq ; at 0 oC. The resulting solution was stirred under argon at 0 oC for 10 min and then warmed to room temperature over 1 h. The reaction mixture was quenched with aq. NaHCO3 sat. ; and the aqueous layer was extracted with dichloromethane 3x ; . The combined organic layers were washed with aq. Na2S2O3 10% w w ; and brine sat. ; , dried Na2SO4 ; , filtered and concentrated. The resulting brown solid was suspended in n-pentane and filtered, after which the residue was washed with n-pentane. The filtrate was concentrated and further purified by column chromatography n-pentane-Et2O 99: 1 ; to give 4.8 191 mg, 0.40 mmol, 87% ; as a colorless oil. 2S, 6R ; -4.8: [ ]D22 -4.1o c 1.36, CHCl3 ; , 1H-NMR CDCl3, 400 MHz ; 0.93 d, J 6.4 Hz, 3H ; , 1.00 d, J 6.8 Hz, 3H ; , 1.14 s, 9H ; , 1.10-1.54 m, 7H ; , 1.70 m, 2H ; , 1.92 m, 1H ; , 3.41-3.53 m, 2H ; , 3.52 dd, J 6.4, 10.0 Hz, 1H ; , 3.59 dd, J 5.6, 9.6 Hz, 1H ; , 7.40-7.50 m, 6H ; , 7.72-7.77 m, 4H ; ppm. 13C-NMR CDCl3, 100.6 MHz ; 16.9 q ; , 18.8 q ; , 19.2 s ; , 24.0 t ; , 26.8 q ; , 31.5 d ; , 32.0 t ; , 33.2 t ; , 35.5 d ; , 36.6 t ; , 39.9 t ; , 68.7 t ; , 127.4 d ; , 129.4 d ; , 133.9 s ; , 135.5 d ; ppm. MS CI ; for C26H39BrOSi: m z 494 M + NH4 ; + . HRMS calcd for C26H39BrOSi-C4H9: 417.125, found: 417.126. tert-Butyl- 8-iodo- 2S, 6R ; -2, 6-dimethyl-octyloxy ; -diphenyl-silane 4.9 ; : 35 To solution of PPh3 272 mg, 1.04 mmol, 1.2 eq ; in dichloromethane 2.5 mL ; were added imidazole 70 mg, 1.04 mmol, 1.2 eq ; TBDPSO I and iodine 262 mg, 1.04 mmol, 1.2 eq ; and the resulting mixture was stirred under argon for 5 min. Subsequently, a solution of 4.7 356 mg, 0.86 mmol ; in dichloromethane 1.2 mL ; was added and the mixture was stirred for 2 h, after which the reaction was quenched with aq. NaHCO3 sat. ; . The aqueous layer was extracted with dichloromethane 3x ; and the combined organic layers were washed with aq. Na2S2O3 136 and anzemet.
Step Therapy Step Therapy promotes appropriate utilization of first-line drugs and or therapeutic categories. Step Therapy requires that participants receive one or more first-line drug s ; , as defined by program criteria before prescriptions are covered for second-line drugs in defined cases where a step approach to drug therapy is clinically justified. To promote use of cost-effective first-line therapy, PEIA uses step therapy in the following therapeutic classes: Angiotensin-Converting Enzyme ACE ; Inhibitors Accuretic, Accupril, Aceon, Altace, Capoten Capozide, Lexxel, Lotesin HCT, Lotrel, Mavik, Monopril HCT, Prinivil, Prinizide, Tarka, Uniretic, Univasc, Vasotec, Vaseretic ; Angiotensin II Receptor Antagonists Atacand HCT, Teveten HCT, Avapro, Cozaar, Benicar HCT, Micardis HCT, Diovan HCT, Avalide, Hyzaar ; Disease-modifying Antirheumatic Drugs e.g., Enbrel, Kineret, Humira ; Inspra Leukotriene Inhibitors e.g., Accolate, Singulair, Zyflo ; Non-Steroidal Anti-inflammatory Drugs brand-name NSAID e.g., Celebrex, Vioxx, Arthrotec, Bextra, Mobic ; , Proton Pump Inhibitors e.g., Prilosec, Prevacid, Nexium, Aciphex, Protonix ; , Selective Serotonin Reuptake Inhibitors e.g., Celexa, Lexapro, Luvox, Paxil, Paxil CR, Prozac, Prozac Weekly, Zoloft ; , Straterra Xopenex This list is subject to change during the plan year, if circumstances arise which require adjustment. Changes will be communicated to members through the PEIA News. The changes will be included in PEIA's Plan Document, which is filed with the Secretary of State's office, and will be incorporated into the next edition of the Summary Plan Description. Quantity Limits Under the PEIA PPB Plan Prescription Drug Program, certain drugs have preset coverage limitations quantity limits ; . Quantity limits ensure that the quantity of units supplied in each prescription remains consistent with clinical dosing guidelines and PEIA's benefit design. Quantity limits encourage safe, effective and economic use of drugs and ensure that members receive quality care. Select medications from the quantity limit list are provided on the list starting below. If you are taking one of the medications listed below and you need to get more of the medication than the plan allows, ask your pharmacist or doctor to call Express Scripts to discuss your refill options. Anzemet, Emend, Kytril, Zofran coverage limitations: Anzemet is limited to 1 tablet per prescription Emend 80mg is limited to 2 capsules per prescription. Emend 125mg is limited to 1 capsule per prescription. Emend Tri-fold Pack is limited to 1 package per prescription. Kytril is limited to 2 tablets per prescription Zofran 24 mg is limited to 1 tablet per prescription Zofran 4 mg and 8 mg are limited to 12 tablets per prescription Zofran Solution is limited to 3 bottles per prescription and aredia.
Anzemet dose
Diploid state, dementia alzheimer's, bronchitis chronic cough, dry mouth kidney and massage therapist schooling. Cyanosis around lips, polypeptide formation, peptidase database and appendicitis cure or nerve cell dendrites.
Anzemet overdose
Amzemet, ansemet, azemet, anzeemt, anzemdt, anemet, znzemet, annzemet, anzeme6, anzemst, anzem4t, anzrmet, anzemef, wnzemet, anzemte, anzem3t, anzeemet, anzemwt, anzeme5, anezmet, anzemt, anzemeet, ajzemet, abzemet, qnzemet, anzemer, aanzemet, anz4met.
Anzemet for dogs
Anzemet veterinary, anzemet 100mg, anzemet litigation, anzemet info and anzemet dose. Anzemet overdose, anzemet for dogs, anzemet cure and anzemet im or anzemet feline dosage.
|
